Ibrahim Akin1, MD; Ahmed A. Khattab2, MD; Heinz Joachim Büttner3, MD; Ralph Toelg1, MD; Volker Geist1, MD; Franz-Josef Neumann3, MD; Gert Richardt1, MD; Mohamed Abdel-Wahab1*, MD
1. Herzzentrum, Segeberger Kliniken GmbH, Bad Segeberg, Germany; 2. Cardiology Department, Bern University Hospital, Bern, Switzerland; 3. Herzzentrum Bad Krozingen, Bad Krozingen, Germany
Aims: Bivalirudin has emerged as a meaningful alternative to heparin in patients undergoing percutaneous coronary intervention (PCI). To date, it is unclear whether bivalirudin has advant